This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Samarium Sm-153 is a radiopharmaceutical indicated in the treatment of bone pain in patients with skeletal metastases.
- Generic Name
- Samarium Sm-153
- DrugBank Accession Number
- DB12905
- Background
Samarium 153 has been used in trials studying the supportive care of Pain, Lung Cancer, Breast Cancer, Prostate Cancer, and Metastatic Cancer.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Samarium Sm-153 (DB12905)
- Weight
- Average: 152.9221
Monoisotopic: 152.922093907 - Chemical Formula
- Sm
- Synonyms
- 153SM
- Samarium 153
- Samarium Sm153
- Samarium-153
- SM-153
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Management of Skeletal pain •••••••••••• •••••••••• •••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of inorganic compounds known as homogeneous lanthanide compounds. These are inorganic compounds containing only metal atoms, with the largest atom being a lanthanide atom.
- Kingdom
- Inorganic compounds
- Super Class
- Homogeneous metal compounds
- Class
- Homogeneous lanthanide compounds
- Sub Class
- Not Available
- Direct Parent
- Homogeneous lanthanide compounds
- Alternative Parents
- Not Available
- Substituents
- Homogeneous lanthanide
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 6Q1KA41UWM
- CAS number
- 15766-00-4
- InChI Key
- KZUNJOHGWZRPMI-AKLPVKDBSA-N
- InChI
- InChI=1S/Sm/i1+3
- IUPAC Name
- (153Sm)samarium
- SMILES
- [153Sm]
References
- General References
- Not Available
- External Links
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Supportive Care Breast Cancer / Lung Cancer / Metastatic Cancer / Pain / Prostate Cancer 1 2 Completed Treatment Prostate Cancer 1 1 Completed Treatment Prostate Cancer 1 1 Recruiting Treatment Bone Cancer / Bone Neoplasm / Metastatic Cancer to the Bone / Metastatic Tumor to the Bone / Solid Tumors 1 1, 2 Completed Treatment Cancer / Metastatic Cancer / Pain 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, solution Intravenous; Parenteral 1.3 GBq/ml - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP 0 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 0 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 0 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 0 m3·mol-1 Chemaxon Polarizability 1.78 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at October 21, 2016 01:10 / Updated at June 12, 2021 10:54